top of page

LUZERN

MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIRAPARIB PLUS AROMATASE INHIBITORS FOR HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER WITH EITHER GERMLINE BRCA-MUTATED OR GERMLINE BRCA-WILDTYPE AND HOMOLOGOUS RECOMBINATION DEFICIENCY

CLINICAL TRIAL DETAILS

MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIRAPARIB PLUS AROMATASE INHIBITORS FOR HORMONE RECEPTOR (HR)-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE METASTATIC BREAST CANCERS WITH EITHER GERMLINE BRCA-MUTATED OR GERMINAL BRCA-WILD-TYPE AND HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) – THE LUZERN STRATEGY. THE PRIMARY GOAL IS TO ASSESS THE EFFICACY –AS DETERMINED BY THE CLINICAL BENEFIT RATE (CBR)– OF NIRAPARIB IN COMBINATION WITH AIS IN UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-POSITIVE/HER2-NEGATIVE BREAST CANCER PATIENTS HARBORING EITHER GBRCAMS OR GBRCAWT AND HRD.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

PRESS RELEASE

home_fondo_you_barra.jpg

​

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

ESMO Breast 2024 lay language summary: https://www.medsir.org/_files/ugd/39f166_b588938836e441009e1fa156c38c3f76.pdf | ESMO Breast 2024 poster: https://www.medsir.org/_files/ugd/39f166_d1243c19897a43b997d3614c778ade1e.pdf | ESMO Breast 2020 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_73ee5d9daa7e496a89081532910422da.pdf | Cancers (MDPI) 2025 publication: https://doi.org/10.3390/cancers17111744

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

Spotlight: LUZERN Breast Cancer Trial: https://www.medsir.org/post/spotlight-luzern-breast-cancer-trial | Stage I in LUZERN Study completed!: https://www.medsir.org/post/stage-i-in-luzern-study-completed | A new milestone achieved in LUZERN Study: 75% recruitment on stage I: https://www.medsir.org/post/a-new-milestone-achieved-in-luzern-study-75-recruitment-on-stage-i | First Patient In LUZERN Study!: https://www.medsir.org/post/first-patient-in-luzern-study | The Beginning of the LUZERN Study: https://www.medsir.org/post/the-beginning-of-the-luzern-study

PHERGAIN SITES

home_fondo_you_barra.jpg
Instituto Valenciano de Oncología (IVO) (Spain) | Hospital Universitari Vall D'Hebron (Spain) | Hospital Clinic (Spain) | Complejo Asistencial de Avila (Spain) | Hospital Universitario Reina Sofía (Spain) | Hospital Universitario Virgen de la Victoria (Spain) | Hospital Clinico Universitario Santiago de Compostela (Spain) | Centro oncologico de Galicia (Spain) | Hospital Universitario Doce de Octubre (Spain) | Hospital Clinico San Carlos (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page